Dehydrovomifoliol

Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

Product Specifications

CAS Number

[39763-33-2]

UNSPSC

12352211

Target

Akt; mTOR

Type

Natural Products

Related Pathways

PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dehydrovomifoliol.html

Purity

98.88

Solubility

10 mM in DMSO

Smiles

CC(/C=C/[C@](C(C)(C1)C)(C(C)=CC1=O)O)=O

Molecular Formula

C13H18O3

Molecular Weight

222.28

References & Citations

[1]Ma J, et al. Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study. Evid Based Complement Alternat Med. 2023 Feb 1;2023:9107598.